Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Korro Bio ( (KRRO) ).
On January 15, 2026, Korro Bio, Inc. updated its corporate presentation for investors and analysts, outlining a pipeline that includes KRRO-121 for hyperammonemia progressing toward a planned regulatory filing in the second half of 2026, an AATD GalNAc-conjugated development candidate expected to be nominated in the first half of 2026, and a liver-focused longevity program and TDP43-targeted ALS program that leverage RNA-editing approaches. The company disclosed it has terminated the REWRITE clinical trial for KRRO-110 in AATD and that its collaboration with Novo Nordisk entered a 12‑month pause in November 2025, signaling a strategic pivot toward newer RNA-editing assets that may reshape its near-term development priorities and investor focus.
The most recent analyst rating on (KRRO) stock is a Sell with a $8.50 price target. To see the full list of analyst forecasts on Korro Bio stock, see the KRRO Stock Forecast page.
Spark’s Take on KRRO Stock
According to Spark, TipRanks’ AI Analyst, KRRO is a Neutral.
The score is pressured primarily by weak financial performance driven by large losses and significant cash burn, plus bearish technicals with the stock far below key moving averages and a negative MACD. Valuation provides limited support due to negative earnings and no dividend yield, while recent corporate actions are mixed, with restructuring and a paused major collaboration weighing on sentiment.
To see Spark’s full report on KRRO stock, click here.
More about Korro Bio
Korro Bio, Inc. is a biopharmaceutical company developing RNA-editing therapies, with a focus on GalNAc-conjugated, subcutaneous liver-targeted programs and intrathecal treatments for central nervous system diseases. Its pipeline includes KRRO-121 for hyperammonemia, an alpha-1 antitrypsin deficiency (AATD) program using GalNAc delivery, a longevity-focused liver program, and an amyotrophic lateral sclerosis (ALS) program targeting TDP43 loss- and gain-of-function.
Average Trading Volume: 510,151
Technical Sentiment Signal: Sell
Current Market Cap: $84.76M
See more insights into KRRO stock on TipRanks’ Stock Analysis page.